Pediatric COVID-19 Vaccination: A Description of Adverse Events or Reactions Reported in Kansans Aged 6 to 17
Keywords:vaccination, adverse drug events, COVID-19 vaccines, vaccine refusal, Kansas
Introduction. There have been widespread concerns about the safety of the COVID-19 vaccines, particularly when it comes to pediatric populations, and it is important to provide information for parents and guardians to make informed decisions. This study sought to identify the adverse events and reactions (AERs) associated with the COVID-19 vaccines in Kansans aged 6 to 17.
Methods. The US Department of Health and Human Services’ “Vaccine Adverse Event Reporting System” (VAERS) database was searched from May 11th, 2021, to April 30th, 2022, for AERs related to COVID-19 vaccines in adolescents ages 6 to 17. Results were grouped by vaccine manufacturer and patient gender.
Results. 159 individuals reported a total of 409 AERS, with an average of 2.6 per person (± 1.7; median = 2; range 1 to 10). Females (n = 95) reported 237 AERs, with an average of 2.5 each (±1.7; median = 2; range 1 to 8); while males (n = 64) reported 172 AERs, with an average of 2.7 each (±1.8; median = 2; range 1 to 8). The most common adverse event associated with Pfizer vaccination was syncope/fainting.
Conclusions. COVID-19 vaccines have undergone intensive monitoring and safety regulations since the onset of the coronavirus. With over 591 million doses administered, there is compelling evidence that the COVID-19 vaccines are safe and effective. Informing the public about the potential AERs of the COVID-19 vaccines in children can help to alleviate vaccine hesitancy and strengthen vaccination confidence.
How to Cite
Copyright (c) 2022 Anna Tri, Kale Mills, Kari Nilsen, Ph.D.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
All articles in the Kansas Journal of Medicine are licensed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC-BY-NC-ND 4.0).